1. The combination of a) a compound of formula I: or a pharmaceutically acceptable salt thereof； and b) one or more agents selected from 5-FU, platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib, or an acceptable salt for the prevention or therapeutic treatment of hyperproliferative disorder. 2. The combination according to claim 1, where the hyperproliferative disorder is a malignant neoplasm. The combination according to claim 2, where the malignant neoplasm is associated with a PTEN mutation. The combination of claim 2, wherein the malignant neoplasm is associated with an AKT mutation, overexpression, or amplification. The combination according to claim 2, where the malignant neoplasm is associated with a PI3K.6 mutation. The combination according to claim 2, where the malignant neoplasm is associated with a mutation or amplification of Her2 / ErbB2.7. The combination according to claim 1, where the combination provides a synergistic effect in the treatment of hyperproliferative disorders. A combination according to any one of claims 2 to 7, wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, melanoma, stomach cancer, colon cancer, kidney cancer, head cancer, neck cancer and glioma. . A combination according to any one of claims 2 to 7, wherein the compound of formula I or a pharmaceutically acceptable salt thereof and 5-FU are administered to a mammal. The combination of claim 9, wherein the malignant neoplasm is breast cancer. The combination of claim 9, further comprising administering oxaliplatin to a mammal. The combination according to claim 11, further including1. Комбинация а) соединения формулы I:или его фармацевтически приемлемой соли； и b) одного или нескольких средств, выбранных из 5-FU, платинового агента, лейковорина, иринотекана, доцетаксела, доксорубицина, гемцитабина, SN-3
